RSS Feed

With Health EU, everyone will have an avatar to manage their health

What if everyone had their own medical avatar – a virtual replica of themselves featuring their own personal data – that could improve the way their health is managed and the way they are treated if they fall ill?

That is the bold proposal put forward by the Health EU project, whose tagline is “Human avatars to prevent and cure diseases”. This international project, led by a consortium headed by EPFL in collaboration with the Institute for Human Organ and Disease Model Technologies based in the Netherlands, recently applied to become a FET Flagship.

FET Flagship is a prestigious multi-disciplinary research programme run by the European Commission that offers €1 billion in funding over ten years.

SCIPROM is proud to be part of this consortium.

For more information about the project please refer to the Health EU website or the recent press release.

If you wish to be part of our Health EU Project or just to manifest your support to our idea, don't hesitate to contact us using our support form!

Innovative Medicines Initiative (IMI) 2 Indicative Topics for Call 14 out

To give potential applicants as much time as possible to form consortia and prepare their proposals, IMI regularly publishes draft topic texts several weeks before the official call launch.

The following topics are currently under consideration for inclusion in future IMI calls for proposals (Call 14):

- Targeted immune intervention for treatment of non-response and remission
- Non-invasive clinical molecular imaging of immune cells
- Development of a platform for federated and privacy-preserving machine learning in support of drug discovery
- Centre of excellence – remote decentralised clinical trials

Details about these topics you can find on the IMI website.

All information regarding future IMI call topics is of course indicative and may be subject to change. Final information about future IMI calls will be communicated after approval by the IMI Governing Board.

Sources: IMI, Euresearch

H2020 SME Instrument: Annotated Proposal Template

The SME network of National Contact Points (NCPs) "Access 4 SMEs" has produced an annotated proposal template for the SME instrument aiming to orient and guide innovative companies in their application by providing appropriate tools and approaches on how to draft a proposal incl. business plan with good chances in the SME Instrument.

We recommend this guide for everyone involved in the preparation of an SME Instrument application! It covers both phases 1 and 2.

You can download the annotated template from the Euresearch website.

Source: Euresearch, Swiss NCP SMEs

Bonseyes success story

Euresearch has just published a Success Story about the Horizon 2020 Project Bonseyes.

Artificial intelligence is projected to add over €13 trillion to the global economy by 2030 but European companies risk being shut out by the ‘data wall’ dominated by such internet giants as Google.

Bonseyes (Platform for Open Development of Systems of Artificial Intelligence) aims to get over the wall using the new power of edge computing and by leveraging Europe’s leadership in embedded systems.

SCIPROM is glad to be part of Bonseyes, supporting the project in terms of management, communication and dissemination since its proposal stage.

H2020 Work Programme 2018-2020 launched today!

The Work Programme 2018-2020 of Horizon 2020 was launched by the European Commission today.

Horizon 2020 is the largest multinational programme dedicated to research & innovation and it is "open to the world". This means that researchers, universities, research organisations, companies and non-governmental organisations from across the globe can apply to participate in the activities of the Work Programme carried out mainly through calls  for proposals.

For your information and further dissemination, please check the EC Press Release.

If you are interested to apply, consult the Horizon 2020 participant portal. The detailed topic descriptions, call conditions and budget information for any of these calls can be found there.

If you have any questions regarding the 2018 calls or if you are looking for support in view of submitting a Horizon2020 project in 2018, do not hesitate to contact us. SCIPROM will be happy to support you from your first idea to the final project report and be on your side all along the project duration.

Sources: EC, Euresearch

Now open: ERC Consolidator Grants Call 2018

ERC Consolidator Grants are designed to support excellent Principal Investigators at the career stage at which they are consolidating their own independent research team.

Up to €2 mio are available for projects of up to 5 years duration.

The call closes on 15 February 2018.

The mandatory templates are available from the Participant Portal once having registered for the call.

For more information, please consult the ERC website. 

Sources: Euresearch, ERC

Draft H2020 Work Programmes 2018-2020

The European Commission is currently making public the draft work programmes 2018-2020 for most of the thematic programmes in Horizon 2020. These drafts are available before their adoption to provide potential participants with the currently expected main lines of the work programmes. The remaining drafts are expected to be released this week.

Please note that they are still in a DRAFT version and as such have not been adopted or endorsed by the European Commission. Any views expressed are the views of the Commission services and may not in any circumstances be regarded as stating an official position of the Commission.

The adoption of the work programme will be announced on the Horizon 2020 website and on the Participant Portal towards end of October 2017. Only the adopted work programmes will have legal value. Information and topic descriptions indicated in these drafts may not appear in the final work programme; and likewise, new elements may be introduced at a later stage.

More information and links to the draft work programmes can be found on the EC website.  

Sources: EC, Euresearch

Innovative Medicines Initiative (IMI): evaluations of IMI1 and IMI2

The Innovative Medicines Initiative has just published the final review of the IMI1 programme, and the mid-term review of IMI2.

The experts conclude that IMI programme ‘remains relevant and justified’ and that ‘positive contributions on the drug development process have been realised’. Positive points recognised in the reports include:

- the IMI role in the creation of collaborative research networks that have enhanced trust between partners from different sectors, and triggered a mind shift as partners came to understand each other’s needs;
- the quality of the research emerging from IMI projects;
- the creation of important resources and tools for drug development, some of which are already being used by researchers in their daily work.

The reports also note that 90% of the people who responded to the online survey agreed that the EU should cooperate with industry in the context of a public-private partnership on health.

Suggestions for improvement concern performance indicators, increasing the involvement of SMEs as well as dissemination and communication of the projects' results.

Read the European Commission's press release on the evaluation
Read the new IMI brochure on results and impacts

Source: IMI

Swiss wins 2017 Nobel Prize in chemistry

Jacques Dubochet of Switzerland's University of Lausanne has been awarded this year’s Nobel prize in chemistry together with two other scientists from Britain and the United States.

Announcing the winners on Wednesday, the Royal Swedish Academy of Sciences said the three scientists helped develop cryo-electron microscopy - a method to have detailed images of life’s complex machineries in atomic resolution.

Dubochet, born in 1942, is a honorary professor of biophysics at Lausanne University and worked at Basel and Geneva Universities.

Innovative Medicines Initiative (IMI) 2 Call 13: Indicative Topics Published

IMI 2 has just published a list of indicative topics for the call 13 which is foreseen to be launched before the end of the year.

The following topics are under consideration for inclusion in future IMI calls for proposals:

- Assessment of the uniqueness of diabetic cardiomyopathy relative to other forms of heart failure using unbiased pheno-mapping approaches
- Genome-environment interactions in inflammatory skin disease
- The value of diagnostics to combat antimicrobial resistance by optimising antibiotic use
- Mitochondrial dysfunction in neurodegeneration
- Support and coordination action for the projects of the neurodegeneration area of the Innovative Medicines Initiative
- A sustainable European induced pluripotent stem cell platform
- Linking digital assessment of mobility to clinical endpoints to drive regulatory acceptance and clinical practice
- Human tumour microenvironment immunoprofiling
- CONCEPTION - continuum of evidence from pregnancy exposures, reproductive toxicology and breastfeeding to improve outcomes now
- Improving the preclinical prediction of adverse effects of pharmaceuticals on the nervous system
- Translational safety biomarker pipeline (TRANSBIOLINE): enabling development and implementation of novel safety biomarkers in clinical trials and diagnosis of disease
- Federated and privacy-preserving machine learning in support of drug discovery
- Pilot programme on a clinical compound bank for repurposing. This programme includes the following topics: Cardiovascular diseases and diabetes, Respiratory diseases, Neurodegenerative diseases and Rare/orphan diseases

Source: IMI2
See Older Posts...